FDA Rejects Moderna's mRNA Flu Vaccine Application
FDA refuses to review Moderna's innovative mRNA flu vaccine over clinical trial design concerns, sending shares down 7%. Company disputes decision citing prior agency approval.
/ 901 items
#Healthcare↓
William Blair Upgrades Nektar on Strong Rezpeg Drug Data
William Blair upgrades Nektar to Outperform following promising long-term data for rezpegaldesleukin in atopic dermatitis treatment with improved safety profile. The results met and in some cases exceeded investor expectations.
Medicare Now Covers Personalis’ NeXT Personal Test for Lung Cancer Monitoring
Personalis announces Medicare coverage for its NeXT Personal MRD test, helping Stage I-III lung cancer patients detect residual disease early and improve care.
EVO301 Meets Primary Endpoint in Phase 2a Study for Moderate-to-Severe Atopic Dermatitis
Evommune reports positive Phase 2a data for EVO301, showing 55% eczema reduction and a safe profile after 12 weeks of treatment.
Oscar Health Q4 Results: Loss Widens but Growth and Profitability Plans Remain
Oscar Health reports wider quarterly losses due to higher medical costs, while revenue grows and the company targets profitability in 2026.
CVS Health Misses 2026 Profit Forecast, Shares Drop
CVS Health falls short of Wall Street's 2026 profit expectations despite beating Q4 estimates. Stock drops 3% as company maintains cautious outlook amid healthcare industry challenges.